Anika Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Anika Therapeutics, Inc. (ANIK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-07-29
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2026-03-31 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2025-03-31 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2024-03-31 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2023-03-31 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 0.00%.
- Anika Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 0.00% 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 0.00% 10-Q · filed 2026-04-30 | |||
| 2025-12-31 | 0.00% 10-K · filed 2026-03-03 | |||
| 2025-06-30 | 0.00% 10-Q · filed 2026-07-29 | |||
| 2025-03-31 | 0.00% 10-Q · filed 2026-04-30 | |||
| 2024-12-31 | 0.00% 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 0.00% 10-Q · filed 2024-11-04 | |||
| 2024-06-30 | 0.00% 10-Q · filed 2025-11-05 | |||
| 2024-03-31 | 0.00% 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | 0.00% 10-K · filed 2026-03-03 | |||
| 2023-09-30 | 0.00% 10-Q · filed 2024-11-04 | |||
| 2023-06-30 | 0.00% 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | 0.00% 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | 0.00% 10-K · filed 2025-03-17 | |||
| 2022-09-30 | 0.00% 10-Q · filed 2023-11-03 | |||
| 2022-06-30 | 0.00% 10-Q · filed 2023-08-08 | |||
| 2022-03-31 | 0.00% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.00% 10-K · filed 2024-03-15 | |||
| 2021-09-30 | 0.00% 10-Q · filed 2022-11-09 | |||
| 2021-06-30 | 0.00% 10-Q · filed 2022-08-04 | |||
| 2021-03-31 | 0.00% 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-11 | |||
| 2020-09-30 | 0.00% 10-Q · filed 2021-11-05 | |||
| 2020-06-30 | 0.00% 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | 0.00% 10-Q · filed 2021-05-07 | |||
| 2019-12-31 | 0.00% 10-K · filed 2022-03-11 | |||
| 2019-09-30 | 0.00% 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | 0.00% 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | 0.00% 10-Q · filed 2020-05-22 | |||
| 2018-12-31 | 0.00% 10-K/A · filed 2021-04-26 | |||
| 2018-09-30 | 0.00% 10-Q · filed 2019-10-28 | |||
| 2018-06-30 | 0.00% 10-Q · filed 2019-07-26 | |||
| 2018-03-31 | 0.00% 10-Q · filed 2019-05-06 | |||
| 2017-12-31 | 0.00% 10-K · filed 2020-03-06 | |||
| 2017-09-30 | 0.00% 10-Q · filed 2018-10-26 | |||
| 2017-06-30 | 0.00% 10-Q · filed 2018-07-31 | |||
| 2017-03-31 | 0.00% 10-Q · filed 2018-05-10 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-02-27 | |||
| 2016-09-30 | 0.00% 10-Q · filed 2017-10-27 | |||
| 2016-06-30 | 0.00% 10-Q · filed 2017-07-28 | |||
| 2016-03-31 | 0.00% 10-Q · filed 2017-05-04 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-02-27 | |||
| 2015-09-30 | 0.00% 10-Q · filed 2016-11-01 | |||
| 2015-06-30 | 0.00% 10-Q · filed 2016-08-01 | |||
| 2015-03-31 | 0.00% 10-Q · filed 2016-05-03 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-02-24 | |||
| 2014-09-30 | 0.00% 10-Q · filed 2014-11-06 | 0.00% 10-Q · filed 2015-11-03 | ||
| 2014-06-30 | 0.00% 10-Q · filed 2014-08-04 | 0.00% 10-Q · filed 2015-08-04 | ||
| 2014-03-31 | 0.00% 10-Q · filed 2015-05-04 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-10 | |||
| 2013-09-30 | 0.00% 10-Q · filed 2014-11-06 | |||
| 2013-06-30 | 0.00% 10-Q · filed 2014-08-04 | 0.00% 10-Q · filed 2014-08-04 | ||
| 2013-03-31 | 0.00% 10-Q · filed 2014-05-05 | |||
| 2012-12-31 | 0.00% 10-K · filed 2015-03-13 | |||
| 2012-09-30 | 0.00% 10-Q · filed 2013-11-05 | 0.00% 10-Q · filed 2012-11-08 | ||
| 2012-06-30 | 0.00% 10-Q · filed 2013-08-06 | |||
| 2012-03-31 | 0.00% 10-Q · filed 2013-05-06 | |||
| 2011-12-31 | 0.00% 10-K · filed 2014-03-13 | |||
| 2011-09-30 | 0.00% 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-07 | 0.00% 10-Q · filed 2012-08-07 | ||
| 2010-12-31 | 0.00% 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |